Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 73

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Interstitial lung disease

Not recruiting

Study on Pirfenidone Inhalation Solution for Patients with Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Metastases to central nervous system+1

Not recruiting

Study on Nivolumab, Ipilimumab, and Bevacizumab for Patients with Non-Small Cell Lung Cancer Spread to the Brain

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Regensburg AöR

Non-small cell lung cancer+1

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitaetsklinikum Essen AöR

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Formycon AG

Erdheim-Chester disease+3

Not recruiting

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Instytut Matki I Dziecka

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Erdheim-Chester disease+3

Not recruiting

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Trametinib Dimethyl Sulfoxide
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Vemurafenib
  • Sponsor:Instytut Matki I Dziecka

Non-small cell lung cancer

Not recruiting

Study of Sitravatinib and Nivolumab vs. Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Chemotherapy and Checkpoint Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Mirati Therapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Novartis Pharma AG

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Asthma

Not recruiting

Study on the Effects of Dexpramipexole in Adolescents and Adults with Eosinophilic Asthma

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.